公开(公告)号：US11046691B1

公开(公告)日：2021-06-29

申请号：US17175578

申请日：2021-02-12

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar Alam ,  Leah Cleary ,  Melissa Fleury ,  Zhonghua Pei ,  Richard Steel ,  James Sutton ,  John E. Knox ,  Zachary E. R. Newby

IPC: C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  C07D239/95 ,  C07D471/04 ,  C07D405/12 ,  C07D403/12 ,  C07D403/14 ,  C07D487/04 ,  C07D401/14 ,  C07D401/12 ,  C07D413/12 ,  C07D519/00 ,  C07D417/12 ,  C07D239/80

Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

公开(公告)号：US20210115016A1

公开(公告)日：2021-04-22

申请号：US16631738

申请日：2018-07-18

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar ALAM ,  Hilary Plake BECK ,  Michael Patrick DILLON ,  Marcos GONZALEZ-LOPEZ ,  Alice Chen RICO ,  James Clifford SUTTON, Jr.

IPC: C07D401/12 ,  C07D403/12 ,  C07D401/14 ,  C07D471/04 ,  C07D487/04 ,  C07D215/12 ,  C07D217/18 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.

公开(公告)号：US20210002297A1

公开(公告)日：2021-01-07

申请号：US17023980

申请日：2020-09-17

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar ALAM ,  Hilary Plake BECK ,  Michael Patrick DILLON ,  Marcos GONZALEZ-LOPEZ ,  James Clifford SUTTON, JR.

IPC: C07D498/04 ,  A61P35/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107 ,  C07D513/04 ,  C07D519/00

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.

公开(公告)号：US12269820B2

公开(公告)日：2025-04-08

申请号：US18188278

申请日：2023-03-22

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Paul A. Barsanti ,  Michael Patrick Dillon ,  Firoz Ali Jaipuri ,  Ying-Zi Xu ,  Xin Linghu

IPC: C07D417/14 ,  A61P35/00

Abstract: Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. The provided compounds are useful Poly ADP-ribose glycohydrolase (PARG) inhibitors. Additional utilities and advantages are described herein.

公开(公告)号：US20250017921A1

公开(公告)日：2025-01-16

申请号：US18043298

申请日：2021-09-07

Applicant: IDEAYA Biosciences Inc.

Inventor： Zineb Mounir ,  Marie-Claire Wagle ,  Nandini Ravindran ,  Divya Pankajakshan ,  Mark R. Lackner

IPC: A61K31/497 ,  A61K31/4545 ,  A61P35/04 ,  C12Q1/6886 ,  G01N33/574

Abstract: A combination therapy is described involving a selective protein kinase C inhibitor and a cMET inhibitor, which is useful for treating metastatic uveal melanoma and other proliferative diseases, such as a tumor having a GNAQ or GNA11 mutation. The combination therapy can be provided by a pharmaceutical product, a method of treatment, or a kit. The combination therapy can involve use of a protein kinase C inhibitor and a cMET inhibitor. Also provided are methods useful for selecting patients or directing a course of treatment. In various examples, the protein kinase C can have the structure according to Formula II.

公开(公告)号：US20230039955A1

公开(公告)日：2023-02-09

申请号：US17853647

申请日：2022-06-29

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar ALAM ,  Hilary Plake BECK ,  Michael Patrick DILLON ,  Marcos GONZALEZ-LOPEZ ,  James Clifford SUTTON, JR.

IPC: C07D498/04 ,  A61P35/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107 ,  C07D513/04 ,  C07D519/00

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2e and R2d have the meanings provided in the specification.

公开(公告)号：US11407764B2

公开(公告)日：2022-08-09

申请号：US17023980

申请日：2020-09-17

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar Alam ,  Hilary Plake Beck ,  Michael Patrick Dillon ,  Marcos Gonzalez-Lopez ,  James Clifford Sutton, Jr.

IPC: C07D498/04 ,  A61P35/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107 ,  C07D513/04 ,  C07D519/00

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.

公开(公告)号：US20220227780A1

公开(公告)日：2022-07-21

申请号：US16648865

申请日：2018-09-25

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Hilary Plake BECK ,  Leah Brigit CLEARY ,  Michael Patrick DILLON ,  Marcos GONZALES-LOPEZ ,  Luis Ruben P. MARTINEZ ,  James Clifford SUTTON

IPC: C07D495/04 ,  A61K31/4365 ,  C07D519/00 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/519 ,  A61P35/00

Abstract: Compounds are provided having Formula (I): wherein R, R1, Cyc and A have the meanings provided herein. The compounds have utility in the treatment of diseases, either alone or in combination with other agents.

公开(公告)号：US20210371855A1

公开(公告)日：2021-12-02

申请号：US17252430

申请日：2019-06-17

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Lisa BELMONT ,  Jeff HAGER ,  Yujiro HATA ,  Lorn KATEGAYA

IPC: C12N15/11 ,  A61P35/00 ,  A61K31/4015 ,  A61K47/68 ,  C12N15/113 ,  C12N9/22 ,  A61K38/46 ,  A61K31/7088 ,  C12N15/86 ,  C12N9/10 ,  A61K38/45 ,  C12Q1/533 ,  A61K45/06

Abstract: The present invention provides methods of negatively modulating the Werner protein (WRN) to inhibit proliferative cells characterized by high microsatellite instability (MSI-H), for example to treat proliferative diseases (such as cancer) characterized by high MSI (MSI-H). Further provided are compositions used in such methods.

公开(公告)号：US11130759B1

公开(公告)日：2021-09-28

申请号：US17175581

申请日：2021-02-12

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar Alam ,  Leah Cleary ,  Melissa Fleury ,  Zhonghua Pei ,  Richard Steel ,  James Sutton ,  John E. Knox ,  Zachary E. R. Newby

IPC: C07D471/04

Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.